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We report that the epidermal growth factor receptor (EGFR) pathway
plays a critical role in regulating cancer stem-like cells (CSCs) in nasopha-
ryngeal carcinoma (NPC), one of the most common malignant tumors in
Southeast Asia. Effects of EGFR on maintaining CSCs are mainly medi-
ated by AKT signaling, and b–catenin is responsible for governing CSC
properties in response to EGFR/AKT activation. Significantly, CSCs are
enriched by cisplatin and decreased by gefitinib in NPC xenograft models.
Upon reimplantation in secondary mice, tumor cells derived from cisplatin-
treated mice grew rapidly, whereas regrowth of tumor cells from gefitinib-
treated mice was severely diminished. We further demonstrate that
expression of EGFR correlates with expression of b–catenin and Nanog in
primary tumor specimens from NPC patients. These findings provide
mechanistic and preclinical evidence supporting the use of gefitinib alone
or in combination with a chemotherapeutic agent in first-line therapy for
patients with NPC. In addition, our results suggest that targeting b–catenin
represents a rational clinical modality for patients whose tumors harbor
activated EGFR or AKT.
Introduction
The epidermal growth factor receptor (EGFR) plays
a critical role in regulating proliferation, differentia-
tion and survival of epithelial cells and tumors of epi-
thelial cell origin [1–3]. Previous studies have revealed
that a single progenitor cell from either embryonic or
adult mouse brain proliferates in response to epider-
mal growth factor (EGF) and generates undifferenti-
ated cells with the properties of neuroepithelial stem
cells [4,5]. EGFR signaling is also required for the
differentiation and maintenance of neural progenitors
from Drosophila embryos [6] and for self-renewal and
differentiation of rat embryonic stem cells [7]. Fur-
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thermore, EGFR modulates a side population (SP) in
human head and neck carcinoma cell lines, which
exhibits stem-cell-like properties [8]. These findings
suggest that EGFR may play an important role in
regulating and maintaining human cancer stem-like
cells (CSCs), a rare subpopulation of self-renewal
cancer cells that could initiate tumors and promote
cancer progression and may account for the failure of
current therapies to eradicate malignant tumors
[9,10].
Wnt/b–catenin signaling pathway has been impli-
cated in regulation of embryonic development, cell
proliferation and self-renewal of CSCs in several
types of tumors [11]. The canonical Wnt pathway
consists of a series of events that eventually lead to
the stabilization and translocation of b–catenin into
the nucleus, where b–catenin accelerates expression of
a broad range of Wnt target genes via binding to the
TCF/LEF family of transcription factors. Recent
studies revealed that the effect of AKT signaling on
stem cells is also mediated by b–catenin [12–14]. Akt
activates b–catenin and induces its nuclear transloca-
tion either by phosphorylation of the C–terminus of
b–catenin at Ser552 [12], or indirectly through phos-
phorylation and inactivation of GSK3b, resulting in
hypophosphorylation of b–catenin at S33/S37/T41
[15].
Naopharyngeal carcinoma (NPC) is a rare epithelial
cancer in most parts of the world. However, it is one
of the most common malignant tumors in Southeast
Asia and southern China, with an incidence of 25–50
per 100 000, which is 25–fold higher than that
observed in western countries [16]. The 5-year survival
for stage IV NPC is only 30%, and poor survival is
often associated with local, regional and systemic
recurrences [17]. Because surgical approaches for NPC
are limited due to the tumor’s inaccessible anatomic
nature and the fact that NPCs are sensitive to radia-
tion, the primary treatment modality for NPC is radio-
therapy with or without chemotherapy [18].
Recent studies showed that NPC contains a small
fraction of cells with properties of CSCs; this tumor
subpopulation plays a critical role in tumorigenesis
and drug resistance [19–21]. In this study, we investi-
gated the role of EGFR in the maintenance, self-
renewal and tumorigenesis of CSCs. We found that
activation of EGFR increased the number of CSCs,
and this effect of EGFR was mediated by phosphati-
dylinositol 3–kinase (PtdIns3K)/AKT/b–catenin signal-
ing. In a NPC xenograft model using nude mice, CSCs
were eradicated by treatment with gefitinib, whereas
they were enriched by treatment with cisplatin. Thus,
our findings reveal distinct effects of gefitinib and
cisplatin on CSCs versus the general tumor cell
population, which may have important clinical impli-
cations for the treatment of NPC.
Results
EGFR expression in NPC cells and inhibition
effects of gefitinib
EGFR is widely expressed in a variety of human
tumors, and inhibition of EGFR has been exploited as
a therapeutic strategy in several solid tumor types
[1,22]. In NPC, EGFR is expressed in 50–80% of
NPC specimens and represents a negative prognostic
factor. Furthermore, EGFR expression was signifi-
cantly linked to low overall survival and shorter time
to progression [23]. To investigate the effect of EGFR
on CSCs in NPC, we first examined expression levels
of EGFR in NPC cell lines. Western blot analyses
revealed that EGFR protein is expressed at various
levels in seven of eight NPC cell lines analyzed
(Fig. 1A). C666–1, the only cell line that did not
express EGFR, exhibits mesenchyme-like morphology
(data not shown). EGFR expression in primary tumor
specimens from 22 NPC patients was assessed using
immunohistochemical staining. Twelve samples
(54.5%) showed detectable levels of EGFR expression.
To determine the inhibitory effects of gefitinib on
NPC cell viability, two cell lines, CNE1 and CNE2,
were used in this study. CNE1 cells are differentiated
and CNE2 cells are poorly differentiated NPC cell
lines [24]. Compared with untreated cells, treatment
with gefitinib for 72 h significantly inhibited cell viabil-
ity of both cell lines, with an IC50 of 2.63 and 3.11 lM
for CNE1 and CNE2, respectively (Fig. 1B).
Regulation of SP cells by EGFR signaling in NPC
SP cells are a small subpopulation of tumor cells
that exhibit CSC properties in a variety of neo-
plasms [25]. A previous study showed that SP cells
in human NPC cell line CNE-2 had stem-like cell
characteristics in vitro and a strong ability to form
tumors in vivo [19]. These cells are characterized by
their high ability to efflux the fluorescent dye Hoe-
chst 33342 from the cytoplasm through ATP-binding
cassette transporters [26,27]. To investigate whether
EGFR could be a regulatory factor for SP cells in
NPC, logarithmically growing CNE1 and CNE2 cells
were subjected to flow cytometric analysis. The
untreated CNE1 and CNE2 cell lines contained 1.6
and 2.5% Hoechst 33342-dull SP cells, respectively.
Treatment with EGF increased the SP by ~ 130% in
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CNE1 cells and 70% in CNE2 cells, and this stimu-
latory effect of EGF was completely blocked by gefi-
tinib (Fig. 1C). Similar results were observed when
gefitinib was replaced with another EGFR tyrosine
kinase inhibitor PD153035 in these experiments
(Fig. 2A).
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Fig. 1. Inhibition of CSCs by gefitinib in NPC. (A) Expression levels of EGFR in eight NPC cell lines. (B) Antiproliferative effects of gefitinib in
CNE1 and CNE2 cell lines. Cells were treated with various concentrations of gefitinib for 72 h, and cell viability was determined by MTT
assay. Error bars indicate standard deviations. The experiment was conducted three times with similar results. (C) Inhibition of SP by
gefitinib (1 lM) in NPC cells. Data are presented as mean  SD (n = 3). *P < 0.01. (D) EGF dependence of tumor spheroid formation of
CNE2 cells. (E) Inhibition of tumor spheroid formation by gefitinib. CNE2 cells derived from primary tumor spheroids were cultured in
suspension growth medium containing EGF and bFGF. Gefitinib was added at 2 lM. Bar = mean  SD (n = 3). *P < 0.01. Scale bars,
100 lm.
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EGFR signaling is essential for tumor spheroid
formation and proliferation
CSCs from several types of cancer have been isolated
and propagated as nonadherent 3D tumor spheroids
that are known to closely mimic phenotypes of in vivo
tumors [28]. To examine whether EGFR signaling is
essential for tumor spheroid formation in NPC, CNE2
cells were cultured in serum-free medium containing
basic fibroblast growth factor (bFGF). When EGF
was supplemented at 10 ngmL1, floating tumor
spheroids were observed after 7 days of cultivation. In
the absence of EGF, however, tumor spheroid forma-
tion was significantly inhibited (Fig. 1D). To further
determine the role of EGFR signaling in the self-
renewal of CSCs, tumor spheroids that formed in the
presence of EGF were dissociated enzymatically to
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Fig. 2. Knockdown of EGFR with siRNA diminishes CSC properties. (A) CNE1 and CNE2 cells were transfected with control siRNA or
siRNA targeting EGFR followed by western blot analysis. In both cell lines, exposure to EGFR siRNA substantially reduced EGFR
expression. (B, C) After transfected with control siRNA or EGFR siRNA, CNE1 and CNE2 cells were treated with or without EGF
(50 ngmL1). Knockdown of EGFR reduced the percentages of the SP of CNE1 and CNE2 at both basal levels and after EGF stimulation.
Data are presented as mean  SD (n = 3). *P < 0.01. (D, E) Depletion of EGFR suppressed tumor spheroid formation of CNE2 cells. Bars
are means  SD (n = 3). *P < 0.01.
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obtain a single-cell suspension and then replated in tis-
sue culture dishes. The cells formed secondary tumor
spheroids in the above growth medium supplemented
with EGF. However, when gefitinib was present in the
medium, tumor spheroid formation was markedly
reduced, and most cells died by day 7 (Fig. 1E).
Knockdown of EGFR diminishes the CSC
phenotype
To further validate the effect of EGFR signaling on
the CSC phenotype, we used small-interfering RNA
(siRNA) to knockdown EGFR expression in CNE1
and CNE2 cells (Fig. 2A). Compared with untransfect-
ed cells, CNE1 and CNE2 cells transfected with EGFR
siRNA displayed reduced percentages of SP, whereas
cells transfected with control siRNA had no obvious
effect. When cells were grown in 50 ngmL1 EGF,
the percentage of SP cells was increased in untransfect-
ed cells and in cells transfected with control siRNA,
but not in cells transfected with EGFR siRNA
(Fig. 2B,C). Next, we measured the effect of EGFR
knockdown on tumor spheroid formation. CNE2 cells
were cultured in serum-free medium containing EGF
and bFGF. Knockdown of EGFR significantly reduced
the number of tumor spheroids (Fig. 2D,E).
EGFR/PtdIns3K/AKT pathway regulates CSC
phenotypes in NPC
Because EGFR signaling exerts its biological functions
mainly through Raf/Mek/ERK and PtdIns3K/AKT
pathways, we asked which pathway mediates the regu-
latory function of EGFR on CSC phenotypes. To this
end, cells were treated for 24 h with EGFR inhibitor
gefitinib (1 lM), PtdIns3K inhibitor LY294002 (15 lM)
or Mek inhibitor PD0325901 (10 lM). Treatment with
EGF increased the percentage of SP cells, and this
effect was blocked by gefitinib or PD153035. When
gefitinib was replaced by LY294002, the PtdIns3K
inhibitor abolished the SP. However, the Mek inhibi-
tor PD0325901 had only a modest effect on the per-
centage of SP cells (Fig. 3A).
We next examined the effects of gefitinib on EGFR
activity and downstream effectors using phospho-spe-
cific antibodies and western blot analysis. As shown in
Fig. 3B, treatment of NPC cells with EGF for 24 h
resulted in marked increases in the phosphorylation
levels of EGFR, AKT and ERK1/2, indicating activa-
tion of EGFR and its downstream effectors by EGF.
When gefitinib or another EGFR inhibitor PD153035
was added, the effects of EGF were diminished
substantially. The molecular target specificity of
LY294002 and PD0325901 was also validated:
LY294002 abolished phosphorylation of AKT, but not
EGFR or ERK. Likewise, PD0325901 inhibited phos-
phorylation of ERK, but not EGFR or AKT.
The effect of EGFR on CSCs is mediated through
downstream b–catenin signaling
The AKT kinase family regulates a variety of cellular
processes including proliferation, survival and
A
B
Fig. 3. EGFR/PtdIns3K/AKT pathway regulates CSC phenotype in
NPC. (A) CNE1 and CNE2 cells were treated with indicated
inhibitors for 24 h followed by FACS SP analyses. EGF-induced
(50 ngmL1) SP cells were diminished by EGFR inhibitor (either
1 lM of gefitinib or 0.5 lM PD153035) or PtdIns3K inhibitor
LY294002 (15 lM), but not by Mek inhibitor PD0325901 (10 lM).
Data are presented as mean  SD (n = 3). *P < 0.01; **P > 0.05.
(B) Cells were treated as described in (A) followed by western blot
analysis. EGF-induced phosphorylation of EGFR, AKT and ERK1/2
was blocked by gefitinib or PD153035.
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metabolism. AKT kinases control these processes
through phosphorylation-mediated regulation of
numerous substrates [29]. As shown above, we have
demonstrated that the effect of EGFR signaling on the
CSC phenotype is mediated by AKT, and b–catenin
was reported to be responsible for mediating the effect
of AKT signaling on stem cells [12,13]. Given these
observations, we next investigated whether b–catenin
plays a role in the EGFR/AKT pathway governing
CSCs in NPC. We first examined the effect of EGFR
signaling on the subcellular localization of b–catenin
in CNE2 cells (Fig. 4A). In untreated cells, b–catenin
was located predominantly at the plasma membrane,
with faint staining distributed in the cytoplasm. When
cells were treated with EGF, b–catenin staining shifted
from the cytoplasmic membrane to the nucleus. Inhibi-
tion of EGFR with gefitinib or inhibition of PtdIns3K
with LY294002 reversed the accumulation of b–catenin
in the nucleus. To confirm the results of immunofluo-
rescent staining, we performed western blot analysis
with an antibody specific for the active form of b–cate-
nin, dephosphorylated on Ser37 or Thr41 (Fig. 4B). In
response to EGF stimulation, expression level of active
form of b–catenin was increased. This effect of EGF
was blocked by gefitinib or LY294002. Importantly,
we further found that EGFR signaling regulates
expression of c–Myc oncogene that is a critical target
of b–catenin [30] as well as an essential factor for
reprogramming adult cells into induced pluripotent
stem [31]. Nanog, a critical stem cell maker, was also
regulated by EGFR signaling, which is in agreement
with a previous report demonstrating that b–catenin
upregulates Nanog expression in embryonic stem cells
[32]. Thus, the above experiments reveal a functional
EGFR/PtdIns3K/AKT/b–catenin axis that regulates
the CSC phenotype in NPC cells.
Subsequently, we investigated the requirement of
b–catenin in the maintenance of CSCs in NPC. To this
end, b–catenin was knocked down with lentivirus-med-
iated shRNAs (Fig. 5A). Compared with cells infected
with the control short hairpin RNA (shRNA)
(sh–green fluorescent protein) lentivirus, cells infected
with sh–b–catenin lentivirus exhibited decreased per-
centage of SP cells at both basal levels and after EGF
stimulation (Fig. 5B). Likewise, knockdown of b–cate-
nin also markedly reduced tumor spheroid formation
in the absence or presence of gefitinib (Fig. 5C). Taken
together, these results provide mechanistic evidence for
a role of b–catenin in maintaining the CSC population
and indicate that b–catenin is a crucial mediator of a
signal transduction pathway downstream of EGFR/
PtdIns3K/AKT.
Gefitinib inhibits CSCs in NPC xenografts
To further evaluate the importance of EGFR signaling
in the maintenance of CSC self-renewal and evaluate
the anti-CSC efficacy of gefitinib in vivo, we performed
experiments in xenograft models with nude mice.
CNE2 cells were subcutaneously implanted into the
flanks of mice. After 2 weeks, mice were treated with
saline, gefitinib or cisplatin, the latter being the most
A B
Fig. 4. The effect of EGFR on the CSC phenotype is mediated through b–catenin signaling. (A) In untreated CNE2 cells, b–catenin was
located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ngmL1) resulted in increased b–catenin nuclear staining, which
was reversed by either gefitinib (1 lM) or LY294002 (15 lM). (B) Western blot analysis showed that elevated expression of active b–catenin,
c–myc and Nanog in response to EGF (50 ngmL1) can be reversed by either gefitinib (1 lM) or LY294002 (15 lM).
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commonly prescribed chemotherapeutic drug for
patients with NPC. Mice were killed 2 weeks later,
and tumor size was measured. Treatment with gefitinib
resulted in a 53% decrease in the mean tumor size,
whereas cisplatin dramatically reduced the tumor size
by 82% when compared to the control treatment
(Fig. 6A). Drug toxicity was evaluated by measuring
body weight of the mice. Gefitinib-treated mice
showed only a modest (7%) weight loss. By contrast,
cisplatin treatment resulted in a 30% reduction in
A
B
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Fig. 5. Knockdown of b–catenin inhibits CSC properties. (A) CNE1 and CNE2 cells were infected with control shRNA lentivirus or b–catenin
shRNA. In both cell lines, b–catenin protein was markedly reduced following expression of b–catenin shRNA. (B) Infection with b–catenin
shRNA lentivirus reduced the percentage of SP cells at the basal level and after EGF (50 ngmL1) stimulation. Bar = mean  SD (n = 3).
*P < 0.01. (C) Compared with cells infected with the control shRNA (sh–green fluorescent protein) lentivirus, cells infected with
sh–b–catenin lentivirus exhibited reduced tumor spheroid formationin the absence or presence of gefitinib. Bar = mean  SD (n = 3).
*P < 0.01. Scale bars, 100 lm.
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body weight (data not shown), underscoring the differ-
ential toxicities of the two drugs.
To determine if CSCs are affected by these treat-
ments, tumor tissues were isolated from animals and
disaggregated into single cells. CSCs were evaluated by
SP analyses (Fig. 6B). Compared with the control, gef-
itinib reduced the percentage of SP cells by 71%,
whereas cisplatin increased the SP-positive populations
by 123%. To further determine the effects of gefitinib
and cisplatin on EGFR/AKT/b–catenin signaling, pri-
mary tumor sections were stained immunohistochemi-
cally with antibodies against different components of
this pathway (Fig. 6D). Although neither cisplatin nor
gefitinib had an effect on the expression levels of
EGFR or AKT1/2, gefitinib, but not cisplatin, mark-
edly inhibited phosphorylation of EGFR and AKT.
Importantly, whereas tumors from control mice exhib-
ited faint and diffused staining of b–catenin, treatment
with cisplatin resulted in strong nuclear accumulation
of the protein that was barely noticeable in tumors
treated with gefitinib. Furthermore, the stem cell
maker Nanog was reduced by gefitinib and moderately
increased by cisplatin.
To determine tumorigenic potential of the residual
cancer cells spared by drug treatments, we performed
a more definitive assay to evaluate their self-renewal
ability in nude mice [33]. For this purpose, 1 9 105 liv-
ing cells dissociated from primary xenografts were
reimplanted into nude mice to assess the development
of secondary tumors. Analysis of the resulting tumors
from each group revealed that cancer cells from cis-
platin-treated mice grew rapidly and formed visible
A
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Fig. 6. Inhibition of CSCs by gefitinib in NPC xenografts. (A) Nude mice harboring CNE2 cell xenografts were treated with saline, gefitinib,
or cisplatin for 2 weeks as described in Materials and methods. Graphs represent mean volume  SD (n = 6). P < 0.01. (B, C) Cells
dissociated from primary xenografts were subjected to FACS analyses. Percentages of SP cells were significantly decreased by gefitinib
and increased by cisplatin. Bar = mean  SD (n = 3). *P < 0.01. (D) Immunohistochemical staining of primary tumors from the mouse
model. Photographs were taken at 9200 magnification. (E) Cells from primary xenografts were reimplanted into nude mice for development
of secondary tumors. Gefitinib abrogated tumor regeneration in secondary mice. Graphs represent mean volume  SD (n = 6).
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tumors by day 7, whereas cells from the control group
produced tumors by day 11. By contrast, the regrowth
capability of cells from gefitinib-treated mice was
severely diminished in the recipient animals. At
24 days, tumors derived from xenografts of cisplatin-
treated mice reached an average size of
1.42  0.09 cm3, 1.4 times larger than those from the
control mice (1.01  0.18 cm3) (Fig. 6E). The above
xenograft experiments were performed in duplicate,
with similar results obtained. In summary, our in vitro
and in vivo experiments indicate that gefitinib preferen-
tially targets CSCs and eliminates tumor cell regrowth,
whereas cisplatin predominantly kills the bulk popula-
tion of the tumor, leading to enrichment of CSC and
fostering tumor regrowth.
Expression of EGFR, b–catenin and Nanog is
correlated in human NPC samples
Our in vitro and in vivo experiments demonstrate that
CSCs are regulated by EGFR signaling. To determine
whether the same effect of EGFR occurs in primary
tumors from NPC patients, we performed an immuno-
histochemical analysis using a tumor tissue microarray
consisting of paraffin-embedded NPC samples derived
from 22 patients using antibodies against EGFR,
b–catenin and Nanog. In addition, the microarray
slides also contain cores from normal nasopharyngeal
epithelial tissues, used as negative controls (Fig. 7A).
Positive immunostaining for EGFR was found in 12
of 22 tumors (54.5%). Eleven of the 12 (92%)
A B
Fig. 7. Correlation of expression of EGFR, b–catenin, and Nanog in human NPC samples. (A) Immunohistochemical studies of
representative NPC specimens showing staining of EGFR, b–catenin and Nanog. Normal and hyperplastic nasopharyngeal tissues were
included as controls. Photographs were taken at 9200 magnification. (B) Expression of EGFR is associated with that of both b–catenin
(P < 0.01) and Nanog (P < 0.05), and immunoreactivity of b–catenin is associated with that of Nanog (P < 0.01).
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specimens that stained positively for EGFR also dis-
played both b–catenin and Nanog immunoreactivity.
Among the 10 EGFR-negative specimens, three dis-
played both b–catenin and Nanog staining, whereas
six showed neither b–catenin nor Nanog staining, and
one stained only for Nanog (Fig. 7B, upper and mid-
dle graphs). Importantly, both b–catenin and Nanog
displayed nuclear staining patterns in cancer tissues,
whereas b–catenin showed cell membrane localization
and Nanog exhibited cytoplasmic distribution in
hyperplasia specimens. Statistical analysis of these
results revealed that EGFR positivity is significantly
associated with that of b–catenin and Nanog (P < 0.01
and P < 0.05, respectively). Intriguingly, immunoreac-
tivity of b–catenin also correlated significantly with
that of Nanog (P < 0.01), with 12 of 22 tumors (58%)
tumors displaying both b–catenin and Nanog staining,
and 7 of 22 (34%) tumors displaying neither b–catenin
nor Nanog staining (Fig. 7B, lower graph).
Discussion
We have shown that the EGFR pathway plays an
important role in regulation of CSC properties in NPC.
We found that CSC numbers are increased by EGF and
suppressed not only by the EGFR specific inhibitors
gefitinib or PD153035, but also by siRNA-mediated
knockdown of EGFR. It has been reported previously
that gefitinib inhibits ABC transporters involved in the
generation of the SP phenotype [34,35]. Our experi-
ments with siRNA-mediated knockdown of EGFR sug-
gested that EGFR signaling is essential for the CSC
phenotype and inhibition of EGFR by gefitinib contrib-
utes significantly to suppression of SP cells. We further
demonstrated that regulation of the CSC phenotype by
EGFR is dependent mainly on the PtdIns3K/AKT
pathway. b–Catenin is a key effector of Wnt signaling
and is also a substrate of AKT. AKT stimulates b–cate-
nin nuclear translocation and activation either directly
through phosphorylation of b–catenin at S552 [12], or
indirectly through phosphorylation and inactivation of
GSK3b, resulting in hypophosphorylation of b–catenin
at S33/S37/T41 [15]. By immunofluorescent staining
and western blot analysis, we have elucidated a func-
tional EGFR/PtdIns3K/AKT/b–catenin axis that regu-
lates the CSC phenotype in NPC cells. In response to
EGF, b–catenin is translocated from the plasma mem-
brane/cytoplasm to the nucleus. Treating cells with
either gefitinib or LY294002, however, prevented EGF-
induced b–catenin nuclear localization. We also showed
that genetic inhibition of b–catenin expression via len-
tiviral shRNA blocks the effect of EGF stimulation. In
NPC xenograft models, we found that residual CSCs
spared by drug treatment were reduced in gefitinib-trea-
ted mice and enriched in cisplatin-treated animals.
These results reveal profound differences between the
effects of gefitinib and cisplatin on CSCs versus the
bulk tumor cell population of a NPC. Importantly, our
study also provides clinical evidence that expression of
EGFR correlates significantly with that of b–catenin
and Nanog in primary tumor specimens from NPC
patients. Thus, our results demonstrate for the first time
a critical role of b–catenin in mediating the effect of
EGFR/PtdIns3K/AKT signaling on CSCs in NPC.
The generation of a continuously growing tumor is
a fundamental property of CSCs. In NPC xenograft
models, we determined that CSCs among the residual
tumor cells spared by drug treatment in ‘first-genera-
tion’ mice were reduced by gefitinib but not by cis-
platin. In fact, treatment with cisplatin actually
increased the proportion of residual cell with CSC
properties. In the secondarily transplanted mice, cells
transplanted from the cisplatin-treated first-generation
mice grew more rapidly and formed larger tumors
compared with the cells from a control group. By con-
trast, cells transplanted from the gefitinib-treated mice
developed tumors that were barely noticeable in the
second generation animals. These results reveal distinct
effects of gefitinib and cisplatin on CSCs versus the
bulk tumor cell population.
Our findings have potential clinical implications.
Gefitinib was the first targeted drug to enter clinical
use for the treatment of nonsmall cell lung cancer [36].
Subsequently, it has been evaluated in patients with
different epithelial cancers with variable responses [36].
Several multicenter phase III clinical trials in patients
with nonsmall cell lung cancer demonstrated that
patients with activating EGFR mutations have signifi-
cantly longer progression-free survival if they are trea-
ted with gefitinib as a first-line therapy than if treated
with cisplatin [37–39]. In a phase II study of NPC
patients who had recurrent or metastatic tumors after
prior platinum-based chemotherapy, gefitinib had little
activity as a monotherapy [40]. However, the failure of
this clinical trial may be explained by the inability of
gefitinib to target CSCs that had accumulated more
mutations under the selection pressure of the first-line
chemotherapeutic agents such as cisplatin. In accord
with our assumption, a recent phase II study of NPC
employing the EGFR inhibitor cetuximab, in combina-
tion with other therapies, showed significant and
encouraging improvement over previous modalities.
The trial, consisting of concurrent cetuximab-cisplatin
and radiotherapy in NPC, resulted in a 2-year distant-
metastases-free survival of 92.8% and a loco-regional
failure-free rate of 93% [41]. In this study, we establish
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potent anti-CSC activity of gefitinib in xenograft mod-
els of NPC. Our results provide not only strong pre-
clinical evidence, but also a mechanism supporting the
use of gefitinib in combination with a chemotherapeu-
tic agent in first-line therapy for patients with NPC.
Resistance to gefitinib or other EGFR tyrosine
kinase inhibitors represents a major therapeutic chal-
lenge. Several clinical studies have shown that despite
initial responses to gefitinib, all patients will eventually
develop resistance to this agent. The EGFR T790M
point mutation, c–Met oncogene amplification, and
PtdIns3K/AKT activation account for most of the
acquired resistance seen in the clinic [42,43]. In line with
these observations, we have provided evidence that the
EGFR/AKT/b–catenin axis regulates CSCs that are
preferentially targeted by gefitinib, and modulation of
various components of the pathway was able to alter
the effects of gefitinib on CSC properties. This suggests
that resistance to gefitinib or other EGFR inhibitors in
NPC may result from aberrant activation of any com-
ponent of the EGFR/AKT/b–catenin pathway. Since
we showed that AKT, but not ERK, is the major medi-
ator of EGFR in regulating the CSC phenotype, our
results provide the rationale for targeting AKT to over-
come gefitinib resistance conferred by either EGFR
mutations or by EGFR-independent activation of AKT
such as c-Met amplification, ErbB3 overexpression, or
loss of PTEN. In addition, our findings also suggest
that activation of b–catenin is sufficient to confer resis-
tance to gefitinib and that targeting b–catenin may rep-
resent an effective modality for patients whose tumors
harbor activated EGFR or AKT.
EGFR and Notch pathway interaction have funda-
mental roles in regulating stem and progenitor cell sig-
naling in Drosophila, Caenorhabditis elegans, and
mammals [44]. Recently it was found that b–catenin
activates Notch signaling through inducing Hes1 and
downregulating Atoh1 [45]. Interestingly, a more recent
study with NPC cell lines found that Notch signaling
was highly activated in SP cells and Notch inhibition
resulted in depletion of SP [46]. Here we showed that
effects of EGFR signaling on SP and tumor spheroids
are mediated by b–catenin. SP cells possess CSC proper-
ties and are regulated by drug transporters ABCG2,
ABCB1 and ABCC1–5 [25]. Our results suggest that
b–catenin may represent a missing link connecting
EGFR and Notch pathways. Thus, Notch signaling
could be activated in response to EGF stimulation in
our system and this possibility is currently under investi-
gation.
In conclusion, our results show that EGFR signaling
plays a crucial role in the regulation of stem cells of
nasopharyngeal cancer. EGFR exerts these effects
through the downstream effectors AKT/b–catenin.
Importantly, the EGFR tyrosine kinase inhibitor
gefitinib preferentially targets the CSC population. By
contrast, the chemotherapeutic agent cisplatin predom-
inantly eliminates the general tumor cell population.
These findings provide preclinical evidence supporting
the use of gefitinib alone or in combination with a che-
motherapeutic agent in first-line therapy for patients
with NPC. In addition, our results suggest that target-
ing b–catenin represents a rational clinical modality
for patients whose tumors harbor activated EGFR or
AKT.
Materials and methods
Cell lines and reagents
All cell lines were preserved in our laboratory. The NPC cell
lines CNE1, CNE2, HNE1, HONE1, SUNE1, C666–1 and
5–8F were maintained in RPMI–1640 medium supplemented
with 10% FBS. A normal human nasopharyngeal epithelial
cell line, NP69, was maintained in keratinocyte–serum-free
medium (SFM) supplemented with bovine pituitary extract
and recombinant EGF (Invitrogen, Carlsbad, CA, USA).
Gefitinib (AstraZeneca, Wilmington, DE, USA) was pur-
chased from the Pharmacy of Nanfang Hospital of South
Medical University. Cisplatin, Hoechst 33342, propidium
iodide and LY294002 were from Sigma-Aldrich (St. Louis,
MO, USA). PD0325901 and PD153035 were from Calbio-
chem (Billerica, MA, USA). Antibodies against the follow-
ing proteins were used: EGFR, phospho-EGFR and
phospho-AKT (Cell Signaling Technology, Danvers, MA,
USA); AKT, ERK1/2, phospho-ERK1/2, b–catenin, Nanog
and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA,
USA); active b-catenin (Millipore, Temecula, CA, USA).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide cell viability assay
The inhibitory effect of gefitinib on NPC cell viability was
evaluated by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide (MTT; Sigma-Aldrich). CNE1 or
CNE2 cells were seeded on a 96-well culture plates at a
density of 1500 cells per well and treated with increasing
concentrations of gefitinib as indicated in the figure. MTT
reagent was added to the plate 72 h after treatment and
absorbance was measured at 590 nm.
Tumor spheroid formation assay
Tumor spheroid culture was performed as described previ-
ously [28]. Single cells were plated in Ultra Low Attach-
ment plates (Corning, Acton, MA, USA) in serum-free
Dulbecco’s modified Eagle’s medium–F12 supplemented
FEBS Journal 280 (2013) 2027–2041 ª 2013 The Authors Journal compilation ª 2013 FEBS 2037
L. Ma et al. Inhibition of cancer stem-like cells by gefitinib
with 10 ngmL1 bFGF, 10 ngmL1 EGF and B27 (all
from Invitrogen). Under these conditions, the cells grew in
suspension as spherical clusters. To assess whether spheroid
formation is EGF-dependent, cells were cultured in the
above medium with or without EGF. Primary spheroids
were dissociated enzymatically with trypsin to obtain a sin-
gle-cell suspension and then replated to evaluate self-
renewal by formation of secondary tumor spheroids.
SP analysis
CNE1 and CNE2 cells in logarithmic growth phase were
serum-starved for 24 h followed by 16 h treatment with
EGF (50 ngmL1) in the absence or presence of gefitinib
(1 lM). Subsequently, cells were suspended in Dulbecco’s
modified Eagle’s medium plus 2% FBS at 1 9 106
cellsmL1 and stained with Hoechst 33342 dye (5 lgmL1)
for 90 min at 37 °C with continuous mixing. Following incu-
bation, cells were washed with ice-cold NaCl/Pi, stained with
propidium iodide (1 lgmL1) and maintained at 4 °C for
flow cytometric analyses and for sorting of SP fraction using
a FACSAria Flow cytometer (Beckton Dickson, Franklin
Lakes, NJ, USA). The Hoechst dye was excited with an UV
laser at 351–364 nm, and its fluorescence was measured with
a 515-nm side population filter (Hoechst blue) and a 608
EFLP optical filter (Hoechst red). A 540 DSP filter was used
to separate the emission wavelengths.
Western blot analysis
Cells were lysed, and then equal amount of protein were
subjected to electrophoresis on a SDS/PAGE gel. The sepa-
rated proteins were transferred to poly(vinylidene difluo-
ride) membranes (Millipore) and probed with appropriate
primary antibodies. Protein bands were detected by using
enhanced chemiluminescence reagents (Pierce Biotechnol-
ogy, Rockford, IL, USA).
Immunohistochemistry
For immunohistochemistry, paraffin-embedded sections
were deparaffinized in xylene and rehydrated in a graded
alcohol series. Antigen retrieval was performed by boiling
the slide preparations in 10 mM sodium citrate buffer,
pH 6.0. Staining was carried out using an EliVision Plus
Kit (Maixin Bio, Beijing, China), according to the manu-
facturer’s protocol. DAB was used as a substrate for perox-
idase, and expression levels were evaluated following
criteria reported elsewhere [47].
Immunofluorescent staining
For immunofluorescent staining, cells were grown on the
surface of cover slides and fixed with 4% paraformalde-
hyde. After rehydration in NaCl/Pi, the fixed cells were
incubated with respective primary antibodies at room tem-
perature for 1 h or at 4 °C overnight. Fluorescein isothio-
cyanate-conjugated secondary antibodies were incubated
for 30 min at room temperature. The nuclei were stained
with 2,6–diaminopimelic acid. Sections were examined with
a Nikon Eclipse 80i fluorescent microscope (Nikon Instru-
ments, Inc., Melville, NY, USA).
Lentiviral constructs and infection of NPC cells
Both pLKO.1 lentiviral shRNA vector and control shRNA
targeting GFP were from Sigma-Aldrich. The b–catenin
targeting sequence, GCTTGGAATGAGACTGCTGAT,
has been described previously [48]. The sense and antisense
oligonucleotides were annealed and ligated into pLKO.1
lentiviral vector. The viruses were then packaged in 293T
cells according to standard protocols. Viral production and
infection of target cells were previously described [49].
Infected cells were selected using 2 lgmL1 puromycin.
In vivo tumorigenicity assay
Animal studies were conducted in strict accordance with
the principles and procedures approved by the Committee
on the Ethics of Animal Experiments of Southern Medical
University. Nude mice (BALB/C nu/nu) were fed auto-
claved water and laboratory rodent chow. A volume of
100 lL of culture medium mixed with Matrigel (BD Bio-
sciences, San Jose, CA, USA) containing 3 9 106 CNE2
cells was transplanted into the flanks of mice by subcutane-
ous injection. Two weeks after implantation, the mice were
randomly separated into different treatment groups (six
mice per arm) and subjected to one of the following treat-
ments: group 1, control mice receiving either intraperitone-
ally injected or orally administrated control solvent;
group 2, mice treated with gefitinib administrated orally at
150 mgkg1 each every day; and group 3, mice treated
with cisplatin injected intraperitoneally twice weekly at
3 mgkg1. The animals were monitored daily, and tumor
volumes were measured every 3 days using a caliper slide
rule. Tumor volume was calculated as follows: V = 1/2
(width2 9 length).
After treatment for 2 weeks, animals were humanely
killed and tumors harvested. To obtain a single-cell suspen-
sion, tumors were minced using scalpels and incubated in
RPMI–1640 medium containing collagenase/hyaluronidase
at 37 °C for 60 min. The tissues were further dissociated by
pipet trituration and then passed through a 40-lm nylon
mesh to produce a single-cell suspension used for subse-
quent experiments. In the secondary tumor experiment,
1 9 105 cells dissociated from first-generation tumors were
implanted into the flanks of recipient mouse (six mice per
group).
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Statistical analysis
Data were expressed as means  SD. Significant differences
between groups were determined by analysis of variance
and by Student’s t–test. Graphs summarizing immunohisto-
chemical staining results were analyzed using the Fisher’s
exact test. Differences were considered significant when the
P < 0.05.
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